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Myeloid Hyperplasia in the SENCAR Mouse:
Differentiation from Granulocytic Leukemia
by Richard E. Long,* Gary Knutsen,t and Merrel Robinsont
The term myeloid hyperplasia has been used interchangeably with many other terms to describe an
increased production of granulocytes, megakaryocytes, and erythrocytes in the spleen and other organs
in the mouse. This process is occasionally misdiagnosed as granulocytic leukemia. This paper reviews
some of the terms used interchangeably with myeloid hyperplasia and describes criteria that can be used
to differentiate myeloid hyperplasia from granulocytic leukemia. Additionally, the results of a study in
which myeloid hyperplasia was induced following the formation of skin tumors in SENCAR mice is
discussed. In this study, positive correlations were found between skin lesions, the spleen weight, and
histologic appearance of the spleen. The liver rarely showed microscopic changes of myeloid hyperplasia
unless the spleen weighed at least 1.0% of the body weight.
Introduction
Many strains ofmice, including the SENCAR stock,
respond to inflammatory stimuli, especially ofthe skin,
by greatly expanding the granulocyte pool with an in-
creased production ofgranulocytes in various organs of
the hematopoietic and lymphoreticular systems. Fre-
quently, proliferation of granulocytic cells is accom-
panied by erythropoiesis, megakaryocytosis, plasma-
cytosis, and reticuloendothelial cell hyperplasia in
various organs of these systems.
Many diagnostic terms, such as myeloid hyperplasia,
leukemoid response, myeloid metaplasia, extramedul-
lary hematopoiesis (EMH), and granulopoiesis have
been used interchangeably to describe this phenome-
non. However, in their pure form all these terms are
not synonymous. For instance the term leukemoid re-
sponse refers to an extreme elevation ofthe white blood
cell count in the peripherial blood (1-3). Myeloid me-
taplasia and EMH refer to the formation and develop-
ment of blood cells outside the bone marrow (1,3), and
granulopoiesis is the formation of granulocytes (1,3).
Myeloid hyperplasia, as we use the term, indicates a
relative (mild to severe) increase in the formation and
development of granulocytes above that level which is
considered normal and is usually associated with an in-
flammatory tissue reaction elsewhere. The use ofthese
terms interchangeably often results in confusion among
those trying to describe and record similar lesions.
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The diagnosis of myeloid hyperplasia is confounded
by the fact that microscopically observed lesions may
mimic those ofgranulocytic leukemia (1,4-7). Although
relatively rare when compared to neoplasms oflympoid
cells, granulocytic leukemia does occur and must be dif-
ferentiated fromseverehyperplasiaofgranulocyticcells
(4,8). The importance ofseparatingmyeloid hyperplasia
from granulocytic leukemia can not be overemphasized.
Many times, the animals in which the hyperplastic or
neoplastic cells are seen have been given a variety of
test materials of potentially significant environmental
impact. Misdiagnosis under these circumstances could
have a profound effect on the outcome ofthe study and
the compounds involved.
In an extensive review ofthe hematopoietic and lym-
phoreticular systems, Dunn details the criteria used to
differentiate granulocytic leukemia and myeloid hyper-
plasia, referred to as "nonmalignant extramedullary
myelopoiesis" in her article. These criteria, as well as
those ofother authors are outlined in Table 1 (1,4,5,7).
Themostimportantcriterionappearstobethepresence
or absence of various stages ofgranulocyte maturation
(1,4,5,7). However, inthe mouseitis difficulttoidentify
all phases ofdevelopment and usually only three stages
can be distinguished. The young or early forms are
larger cells with basophilic cytoplasm, with or without
azurophilic granules and a round or early ring-form nu-
cleus with finely stippled chromatin. The old or mature
formhasapalebasophilicorneutrophiliccytoplasmwith
a ring form nucleus showing early indentation or fully
developed segmentation and coarsely distributed chro-
matin. The intermediate formsinclude allthe remaining
cell stages (1,5).
In this report we will attempt to clarify further some
of the terminology, report the results obtained fromLONG, KNUTSEN, AND ROBINSON
Table 1. Myeloid hyperplasia vs. granulocytic leukemia in the
mouse.
Myeloid hyperplasia
All stages of granulocyte
development present
Erythropoietic activity usually
present
Megakaryocytes are usually
numerous
Frequently associated with
inflammation
Cells are not invasive
Normal tissue of the spleen is
relatively unaffected
Blood is normal or leukocytosis
with mature forms
Hemorrhages are absent
Not transmissible
Not transplantable
Can occur at any age
When the lymph nodes are
involved the cells are usually
confined to the medulla
Bone marrow is involved late
Bone marrow involvement does
not result in destruction of the
bone
Granulocytic leukemia
Usually immature cells with one
stage predominating
Erythropoietic activity absent
Megakaryocytes are few and
present in organs where they
are normally found
Not usually accompanied by
inflammation
Cells are invasive
Normal tissue of the spleen is
extensively replaced
Blood usually contains immature
forms and may have high
white blood count
Hemorrhages are frequent
Transmissible
Transplantable
Usually occurs in mice over 12
months old
When the lymph node is
involved the cells are not
confined to the medulla
Bone marrow is involved early
Bone marrow involvement
results in destruction of the
bone
examination of cases on file, and provide some data from
a study designed to induce myeloid hyperplasia.
Materials and Methods
Reports from three studies at the Health Effects Re-
search Laboratory/Toxicology and Microbiology Divi-
sion (HERL/TMD) at the Environmental Protection
Agency (EPA) were examined. Slides were evaluated
from eight animals that had been diagnosed as having
myeloid (granulocytic) leukemia, leukemoid reaction,
extramedullary hematopoiesis, and/or granulopoiesis in
one or more of the following organs: liver, spleen, and
lymph node.
Inaddition, astudy, using 160 SENCAR mice divided
into four groups of 40 animals each, was performed to
induce myeloid hyperplasia. Groups 1, 2, and 3 were
initiated with one topical application of benzo(a)pyrene
(2.0 mg/kg). Promotion was started 5 days later with
topical application of12-O-tetradecanoylphorbol-13-ace-
tate (TPA) 3 times a week for 15 weeks (7 weeks at 2.0
jig TPA in 0.2 mL of acetone per mouse followed by 8
weeks of 4.0 jig TPA in 0.2 mL of acetone per mouse).
Group 4 was treated topically with 0.2 mL of acetone
per mouse at the time of initiation, following the same
schedule as that used for the promotion of groups 1
through 3. During week 19, the mice in group 2 were
anesthetized with ether, and up to two tumors per an-
imal were removed. The incisions were closed and the
mice were allowed to recover. During the same week,
the mice from group 1 and half ofthe mice (20 animals)
from group 4 (labeled group 4ES) were sacrificed in a
CO2chamber. Theweights ofthebody, liver, and spleen
were recorded, and selected tissues were placed into
10% buffered neutral formalin (BNF) for subsequent
microscopic examination. Duringweek29theremaining
mice in groups 2, 3, and 4 (now labeled group 4LS) were
sacrificed, the weights of the body, liver, and spleen
were recorded, and selected tissues were placed in 10%
BNF for subsequent microscopic examination. Tissues
were processed, embedded in paraffin, sectioned at 5 to
6 ,um, and stained with hematoxylin and eosin for mi-
croscopic examination.
Results
Slides from a previous HERL/TMD study were eval-
uated using the criteria listed in Table 1. Sections from
spleens that had been diagnosed as having granulocytic
leukemia, leukemoidresponse, orEMHwere examined.
Therewas no outstanding feature presentto distinguish
granulocytic leukemia from the leukemoid response. In
fact, the granulocytic cell population of the spleen di-
agnosed as leukemoid response appeared to have the
most immature cell population with the most uniform
stage ofdevelopment, characteristics usually associated
with granulocytic leukemia. The spleens diagnosed as
having EMH in general could be readily differentiated
from those with granulocytic leukemia or leukemoid re-
sponse. They usually had more erythropoietic foci and
fewer numbers of granulocytes. However, one mouse
with EMH was histologically similar to one diagnosed
with leukemoid reaction, except that the former had a
greater number ofmature granulocytes. Based on pre-
viously stated criteria and definitions, it appears that
these cases should have been diaginosed as EMH or
myeloid hyperplasia.
Liver sections diagnosed as having granulocytic leu-
kemia, leukemoid response, or granulopoiesis were also
evaluated. Again there were no discernable differences
between the livers ofmice with leukemoid response and
those with granulocytic leukemia. There was extensive
involvement oftheliverprimarily atthetips ofthe lobes
in all these mice. In two animals, one with granulocytic
leukemia and one with leukemoid response, necrosis of
hepatocytes was accompanied by intense infiltration of
granulocytes. However, in all instances, all stages of
granulocyte development were present, as were a few
megakaryocytes scattered in sinusoids. Occasionally,
small erythropoietic foci were present in livers of mice
with leukemoid response. A large number of mature
and afewimmature granulocytes were found within the
lumens of blood vessels in the liver of one mouse di-
agnosed as having granulocytic leukemia. When the
liveris evaluated alone, the changes observed may lead
to adiagnosis ofgranulocytic leukemia. However, when
these changes are considered with changes seenin other
tissues, a diagnosis of granulocytic leukemia may not
be appropriate.
Thelivers ofmice diagnosed withgranulopoiesis were
less severely affected and contained scattered foci of
granulopoiesis in sinusoids and adjacent to blood ves-
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FIGURE 1. Spleen and liver weights by group. Spleen and liver
weights expressed as a percentage of body weight compared by
groups.
sels. Occasionally smallfoci oferythropoiesis were pres-
ent, but megakaryocytes were not consistently found.
The granulocytes present in the livers were a mixture
of all stages of granulocyte development. The major
difference betweenthese livers andthose described pre-
viously wTas in the number of cells and the amount of
hepatic tissue involved.
The data from our study designed to induce myeloid
hyperplasia showed adifference amongthe groupswhen
the mean spleen weights per group, expressed as a per-
centage of the body weight, were compared (Fig. 1).
The mean spleen weight of group 1, the treated group
sacrificed early, and group 3, the treated group sacri-
ficed at the end ofthe study, were essentially the same.
Mean spleen weights in group 4ES, the half of the ve-
hicle control group sacrificed early, and in group 4LS,
the half of the vehicle control group sacrificed at the
end of the experiment, were essentially the same, and
both were much lower than groups 1 and 3. The mean
spleen weight of group 2, the treated group with the
tumors surgicially removed and sacrificed at the end of
the study, was lower than that in groups 1 and 3 but
slightly higherthanthose in groups 4ES and 4LS. When
the same comparisons were made using the liverweight
expressed as a percentage of the body weight, no dif-
ference was found among any of the groups (Fig. 1).
When the mean liver and spleen weights, expressed
as a percentage of the body weight, were evaluated
based on the number of skin tumors and the presence
of dermal ulcerations not associated with skin tumors,
a definite pattern was seen (Fig. 2). The number ofskin
tumors was also used as a measure of inflammation. In
general, as the number of tumors increased so did the
amount of associated inflammation (ulcerative, but not
always suppurative). There was an increase in the mean
weight ofthe liver and spleen as the number of tumors
increased. The liver and spleen weights were highest
when dermal ulcers, not associated with skin tumors,
were present. The increases in liver and spleen weights
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FIGURE 2. Spleen and liverweights by skin lesions. Spleen and liver
weights expressed as a percentage of body weight compared by
the number of skin tumors present and the presence of dermal
ulceration not associated with skin tumors.
parallel each other in mice that had only skin tumors.
In mice that had dermal ulcerations not associated with
tumors, the difference between the liver and spleen
weights was much greater. This difference was attrib-
utable to the greater increase in liver weight.
Spleen weights appeared to increase as a result of
increased number ofcells ofthe erythrocytic and gran-
ulocytic series in the spleen. Usually this increase was
not detected microscopically until the spleen weighed
0.5 to 0.7% ofthebodyweight. In contrasttothe spleen,
the mild increases in the weight of the liver were not
as readily attributed to cells of the granulocytic or
erythrocytic series and in many cases, no histologic evi-
dence for these increases were found. No granulocytic
precursors were seen in the liver unless the spleen was
also involved, except in two instances. In most cases
the spleen was severely affected and accounted for
greater than 1% ofthe body weight before the liver was
involved. Pathological changes in the lymph nodes were
not observed unless the spleen was severely infiltrated
by granulocytic cells.
Thespleenandlymphnodes were consistentlygrossly
enlarged in animals that had a large number of tumors
or had dermal ulcerations not associated with skin tu-
mors (Figs. 3 and 4). Microscopically, spleens from mice
with no skin lesions had very few randomly scattered
granulopoietic foci in the red pulp. These foci contained
relatively few granulopoietic cells compared tofoci from
spleens of animals bearing skin lesions. In contrast to
the random distributions in the normal spleen, granu-
lopoietic foci first appearedjust beneath the splenic cap-
sule and adjacent to the trabeculae in the red pulp in
animals with skin lesions (Fig. 5). As the number of
granulocytic cells increased, these foci expanded and
formed a rim of proliferating cells beneath the capsule
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FIGURE 3. Dermal ulceration. Note the large area of dermal ulceration over the anterior one-third of the back following treatment with
2pug TPA three times per week for 15 weeks and 4 ,ug TPA three times per week for 8 weeks.
FIGURE 4. Enlarged spleen and peripheral lymph nodes. Mouse had extensive skin tumors.
and around the trabeculae (Fig. 6). In severe cases,
granulocytes and their precursors began filling the red
pulp (Fig. 7). In all instances, megakaryocytes and foci
of erythropoiesis were scattered among the proliferat-
ing granulocytes throughout the red pulp. Although the
white pulp changes were not critically evaluated in this
study, no extreme differences were noted among the
groups. To formulate accurate conclusions on changes
occurring in the white pulp would require a complete
reevaluation of the spleens. In the liver, foci of gran-
ulopoiesis with occasional megakaryocytes were found
adjacent to hepatic and portal vessels as well as in sin-
usoids (Fig. 8). The reaction in the lymph node was
characterized by extensive plasma cell infiltration ofthe
medulla with or without granulocytes and their precur-
sors in medullary cords and sinuses (Fig. 9). Reticu-
loendothelial cell hyperplasia was an inconsistent find-
ing. These changes occurred with approximately equal
frequency and severity in the inguinal and axillary
lymph nodes. The mesenteric lymph nodes were infre-
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FIGURE 5. Mild myeloid hyperplasia in the spleen. Note granulo-
poietic foci adjacent to trabeculae, megakaryocytes, and foci of
erythropoiesis.
quently involved. Only rarely were changes seen in the
mesenteric lymph node without involvement of the ax-
illary and/or inguinal lymph node.
Discussion
Granulocytic leukemia and myeloid hyperplasia are
not always easily distinguished from one another, es-
pecially when only one or two tissues are available for
microscopic examination. In granulocytic leukemia the
cells are immature, usually with one stage predominat-
ing. However, in myeloid hyperplasia, all stages of de-
velopment can be found (1,4,5,7). Other commonly used
criteria for differentiating these two conditions are the
presence oferythropoiesis, megakaryocytes, and an in-
flammatory reaction. These conditions are typically
found with myeloid hyperplasia but are not usually as-
sociated with granulocytic leukemia (1,5,7). When the
number of available tissues is limited, the presence of
capsular invasion, the age of the mouse, and the pres-
ence of hemorrhages should also be considered when
making a diagnosis (1,5,7,8).
However, a thorough macroscopic and microscopic
FIGURE 6. Moderate myeloid hyperplasia in the spleen. Note the
rim of proliferating granulocytic cells adjacent to trabeculae, me-
gakaryocytes, and foci of erythropoiesis.
examination of a complete set of tissues is more likely
to provide information that will enable one to separate
these two conditions (5). Items that should be noted
during the necropsy include: the presence of inflam-
matory conditions; the size of the liver, spleen, and
lymph nodes; the weights of the liver and spleen; and
presence or absence of hemorrhage. Tissues to be col-
lected to facilitate a diagnosis include the spleen, liver,
peripherial lymph nodes, bone marrow (formalin-fixed
and fresh smears), kidneys, adrenals, salivary glands,
and ovaries. If the live animal is available, additional
techniques such as collection of blood for a complete
leukocyte count with a differential count and the har-
vesting of tissue for transmission and transplantation
studies should be done (1,5,7).
The extent of organ involvement can only be deter-
minedifafull set oftissuesis available. Thisinformation
can be most useful in differentiating these two condi-
tions because the order in which the organs are affected
is different in each. In myeloid hyperplasia, the bone
marrow is one of the first tissues to be affected. This
order of occurrence is in contrast to granulocytic leu-
kemia in which bone marrow invovlement occurs late
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FIGURE 7. Severe myeloid hyperplasia in the spleen. Note diffuse
granulopoiesis involving the red pulp, megakaryocytes, and foci
of erythropoiesis. The white pulp was considered to be within
normal limits.
in the course ofthe disease and may be associated with
bone destruction. Additionally, in granulocytic leuke-
mia, the spleen is the first organ affected followed by
the liver. Neoplastic cells infiltrate the lymph nodes,
bone marrow, and other organs during the later stages
of the disease (5,7,8).
The study we conducted was designed so that no tu-
mors or dermal ulcerations would be present on any
animal in group 2 at the end of the experiment. We
discovered the amount of tissue that had to be excised
to ensure complete removal of the skin tumors was so
great that no more than two tumors could be removed
from any one mouse. Therefore, when evaluating ofthe
group data for groups 1, 2, and 3, only those animals
with one or two skin neoplasms were used. In all, 29
mice in group 1, 32 mice in group 2 and 28 mice in group
3 either died early or did not meet the criteria required
for evaluation as outlined above and were thus elimi-
nated from the evaluation.
The presence ofmyeloid hyperplasia at week 19 and
week 29 was reflected by the elevated mean splenic
weight of group 1 and group 3, respectively. In both
groups, the increased mean splenic weight correlated
microscopically with an increase in the number of cells
FIGURE 8. Myeloid hyperplasia in the liver. Note foci of granulo-
poiesis adjacent to vessels as well as in sinusoids.
ofthe granulocytic and erythrocytic series. The absence
of an increased mean splenic weight in the tumor-free,
vehicle control mice (group 4) at the early and the ter-
minalsacrifice suggeststhatthepresenceofskintumors
provided the stimulus for the induction of the myeloid
hyperplasia. The low mean splenic weight ofgroup 2 at
the terminal sacrifice suggests that myeloid hyperplasia
was reversed by the removal of the tumors. The lack
ofcorrelation between increased mean liver weight and
histologic evidence of myeloid hyperplasia in the liver
in mice having one or two skin tumors may have been
due in part to the low level of liver involvement or the
lack of uniform changes within the lobes of the liver.
As the number of skin tumors increased, there was
a trend toward greater liver and spleen weights. The
marked rise in liver and spleen weights when dermal
ulcerations not associated with skin tumors were pres-
ent suggests the associated inflammatory reaction was
a positive stimulus for the initiation of myeloid hyper-
plasia. Increased production ofgranulocytes as a result
of an inflammatory lesion is well documented in the
literature (2,7,9,10). Increased spleen weights in mice
with dermal ulcerations correlated microscopically with
the presence of myeloid hyperplasia. This finding was
to be expected based on reports in the literature (7).
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FIGURE 9. Myeloid metaplasia and plasmacytosis in a lymph node.
Note the severe infiltration of the lymph node by plasma cells.
Scattered foci ofgranulopoiesis andmegakaryocytes are alsopres-
ent.
However, the greater increase in the liverweight when
comparedtothe spleenweightinthepresence ofdermal
ulcerationswasnotexpected andisnoteasilyexplained.
In conclusion, myeloid hyperplasia usually results
from an increased demand for granulocytes and may
affect the spleen, liver, and lymph nodes, as well as
other organs. It is most commonly induced by inflam-
matory conditions. Histologically, the spleen, liver,
lymph nodes, and occasionally other organs may be in-
filtrated by proliferating granulocytes that can some-
times be mistaken for neoplastic cells associated with
granulocyticleukemia. Anumberofmicroscopic criteria
can be applied to help distinguish between the two con-
ditions. However, they are much easier to differentiate
if a complete diagnostic workup is performed.
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